WELLESLEY, Mass.--(BUSINESS WIRE)--NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body’s ability to deliver oxygen to diseased tissues, today announced that John A. Hey, Ph.D., has been appointed Senior Vice President of Preclinical and Early Development. In this role, Dr. Hey will be responsible for the drug discovery and preclinical drug development activities for NormOxys’ platform of novel oxyren compounds, as well as all preclinical research. Dr. Hey will work closely with the NormOxys management team to support the advancement of clinical lead OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin, which is in clinical development for the treatment of two diseases, chronic heart failure and cancer.
